SIC
SGEN

SJS Investment Consulting’s Seagen Inc. Common Stock SGEN Stock Holding History

SJS Investment Consulting’s Portfolio SGEN Stock Details SGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$2.12K – 1668
2023
Q3 		$2.12K Hold
10
– – ﹤0.01% 615
2023
Q2 		$1.93K Hold
10
– – ﹤0.01% 618
2023
Q1 		$2.02K Hold
10
– – ﹤0.01% 600
2022
Q4 		$1.28K Buy
10
+4
+67% +$516 ﹤0.01% 827
2022
Q3 		$1K Buy
+6
New +$977 ﹤0.01% 977
2022
Q1 		$0 Buy
+2
New +$271 ﹤0.01% 1454

Other funds holding SGEN

SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FBC
Fairfield, Bush & Co Darien, Connecticut $203M AUM 38.37% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

SJS Investment Consulting's SGEN Position: Q4 2023 in Review

SJS Investment Consulting sold out of Seagen Inc. Common Stock (SGEN) in Q4 2023, closing a stake of 10 shares — an estimated $2.12K sold.

SJS Investment Consulting first reported a position in SGEN in Q1 2022 and held it in 6 quarters. The position peaked at $2.12K in Q3 2023. 6 funds tracked by Wall St. Rank hold SGEN as of Q4 2023.

  • SJS Investment Consulting reported no remaining Seagen Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • SJS Investment Consulting sold 10 Seagen Inc. Common Stock shares in Q4 2023, an estimated $2.12K.
  • SJS Investment Consulting first reported a position in Seagen Inc. Common Stock in Q1 2022 and held it in 6 quarters.
  • SJS Investment Consulting's Seagen Inc. Common Stock position peaked at $2.12K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Seagen Inc. Common Stock as of Q4 2023.

Based on SJS Investment Consulting's 13F filing for Q4 2023, filed 16 Jan 2024.